Natco Pharma’s finished dosage formulations manufacturing unit in Visakhapatnam has received U.S. Food and Drug Administration’s establishment inspection report with a voluntary action indicated (VAI) classification.The U.S. FDA had conducted an inspection of the facility in Parawada, Visakhapatnam, from August 17-21 and issued Form-483 with four observations. “We hereby notify the company has received EIR from the U.S. FDA on the classification of the above referred inspection as VAI,” Natco Pharma said in a filing on Friday.VAI is one of the three classifications, the U.S. FDA issues implying objectionable conditions or practices were found, during the inspection, but the regulator is not prepared to take or recommend any administrative or regulatory action.Official action indicated (OAI) is another classification and severest, among the three, calling for regulatory and/or administrative actions. No action indicated (NAI) is the third classification and convey no objectionable conditions or practices were found during inspection. Published - November 20, 2026 07:28 pm IST
U.S. FDA issues VAI classification to Natco Pharma’s FDF unit in Vizag
Full Article
Original Source
Read the full article at Thehindu →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.